SWOG clinical trial number
CTSU/NRG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Open
Phase
Abbreviated Title
Phase III Double-Blind Trial, of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status Notes
Temporary Closure - Effective 6/23/21
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Activated by NRG Oncology on 3/12/19.
Activated by SWOG: 7/24/2019
Activated
07/24/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Breast Cancer
Early Therapeutics & Rare Cancers
Treatment
Trastuzumab
Pertuzumab
Atezolizumab
Paclitaxel
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
SWOG Clinical Trial Number
CTSU/AOST2031
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open
SWOG Clinical Trial Number
S2012
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12/02/2021
Accrual
34%
Open
Phase